S&P 500   2,470.50 (-4.41%)
DOW   20,943.51 (-4.44%)
QQQ   182.31 (-4.25%)
AAPL   240.91 (-5.26%)
FB   159.60 (-4.32%)
MSFT   152.11 (-3.55%)
GOOGL   1,102.10 (-5.15%)
AMZN   1,907.70 (-2.16%)
CGC   13.58 (-5.83%)
NVDA   243.07 (-7.79%)
BABA   187.56 (-3.56%)
MU   39.89 (-5.16%)
GE   7.04 (-11.34%)
TSLA   481.56 (-8.10%)
AMD   43.66 (-4.00%)
T   28.05 (-3.77%)
ACB   0.81 (-11.00%)
F   4.40 (-8.90%)
NFLX   364.08 (-3.04%)
BAC   19.77 (-6.88%)
GILD   72.51 (-3.01%)
PRI   84.16 (-4.88%)
DIS   94.92 (-1.74%)
S&P 500   2,470.50 (-4.41%)
DOW   20,943.51 (-4.44%)
QQQ   182.31 (-4.25%)
AAPL   240.91 (-5.26%)
FB   159.60 (-4.32%)
MSFT   152.11 (-3.55%)
GOOGL   1,102.10 (-5.15%)
AMZN   1,907.70 (-2.16%)
CGC   13.58 (-5.83%)
NVDA   243.07 (-7.79%)
BABA   187.56 (-3.56%)
MU   39.89 (-5.16%)
GE   7.04 (-11.34%)
TSLA   481.56 (-8.10%)
AMD   43.66 (-4.00%)
T   28.05 (-3.77%)
ACB   0.81 (-11.00%)
F   4.40 (-8.90%)
NFLX   364.08 (-3.04%)
BAC   19.77 (-6.88%)
GILD   72.51 (-3.01%)
PRI   84.16 (-4.88%)
DIS   94.92 (-1.74%)
S&P 500   2,470.50 (-4.41%)
DOW   20,943.51 (-4.44%)
QQQ   182.31 (-4.25%)
AAPL   240.91 (-5.26%)
FB   159.60 (-4.32%)
MSFT   152.11 (-3.55%)
GOOGL   1,102.10 (-5.15%)
AMZN   1,907.70 (-2.16%)
CGC   13.58 (-5.83%)
NVDA   243.07 (-7.79%)
BABA   187.56 (-3.56%)
MU   39.89 (-5.16%)
GE   7.04 (-11.34%)
TSLA   481.56 (-8.10%)
AMD   43.66 (-4.00%)
T   28.05 (-3.77%)
ACB   0.81 (-11.00%)
F   4.40 (-8.90%)
NFLX   364.08 (-3.04%)
BAC   19.77 (-6.88%)
GILD   72.51 (-3.01%)
PRI   84.16 (-4.88%)
DIS   94.92 (-1.74%)
S&P 500   2,470.50 (-4.41%)
DOW   20,943.51 (-4.44%)
QQQ   182.31 (-4.25%)
AAPL   240.91 (-5.26%)
FB   159.60 (-4.32%)
MSFT   152.11 (-3.55%)
GOOGL   1,102.10 (-5.15%)
AMZN   1,907.70 (-2.16%)
CGC   13.58 (-5.83%)
NVDA   243.07 (-7.79%)
BABA   187.56 (-3.56%)
MU   39.89 (-5.16%)
GE   7.04 (-11.34%)
TSLA   481.56 (-8.10%)
AMD   43.66 (-4.00%)
T   28.05 (-3.77%)
ACB   0.81 (-11.00%)
F   4.40 (-8.90%)
NFLX   364.08 (-3.04%)
BAC   19.77 (-6.88%)
GILD   72.51 (-3.01%)
PRI   84.16 (-4.88%)
DIS   94.92 (-1.74%)
Log in

NASDAQ:CLSD - Clearside Biomedical Stock Price, Forecast & News

$1.51
-0.19 (-11.18 %)
(As of 04/1/2020 04:00 PM ET)
Today's Range
$1.46
Now: $1.51
$1.66
50-Day Range
$1.32
MA: $2.28
$3.25
52-Week Range
$0.56
Now: $1.51
$4.13
Volume239,862 shs
Average Volume1.08 million shs
Market Capitalization$67.75 million
P/E RatioN/A
Dividend YieldN/A
Beta0.82
Clearside Biomedical, Inc., a late-stage clinical biopharmaceutical company, develops pharmacological therapies to restore and preserve vision for people with serious eye diseases. It develops XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of macular edema associated with uveitis, diabetic macular edema, and macular edema associated with retinal vein occlusion. The company was founded in 2011 and is headquartered in Alpharetta, Georgia.
Read More
Clearside Biomedical logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CLSD
CUSIPN/A
Phone678-270-3631

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.17 million
Book Value$0.25 per share

Profitability

Net Income$-30,770,000.00
Net Margins-1,416.02%

Miscellaneous

Employees50
Market Cap$67.75 million
Next Earnings Date5/13/2020 (Estimated)
OptionableOptionable

Receive CLSD News and Ratings via Email

Sign-up to receive the latest news and ratings for CLSD and its competitors with MarketBeat's FREE daily newsletter.


Clearside Biomedical (NASDAQ:CLSD) Frequently Asked Questions

How has Clearside Biomedical's stock been impacted by COVID-19 (Coronavirus)?

Clearside Biomedical's stock was trading at $2.59 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, CLSD shares have decreased by 40.2% and is now trading at $1.55. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Clearside Biomedical?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Clearside Biomedical in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Clearside Biomedical.

When is Clearside Biomedical's next earnings date?

Clearside Biomedical is scheduled to release its next quarterly earnings announcement on Wednesday, May 13th 2020. View our earnings forecast for Clearside Biomedical.

How were Clearside Biomedical's earnings last quarter?

Clearside Biomedical Inc (NASDAQ:CLSD) posted its earnings results on Wednesday, March, 11th. The company reported ($0.07) EPS for the quarter, meeting the consensus estimate of ($0.07). The company earned $1.94 million during the quarter, compared to analysts' expectations of $5.90 million. Clearside Biomedical had a negative return on equity of 246.61% and a negative net margin of 1,416.02%. View Clearside Biomedical's earnings history.

What price target have analysts set for CLSD?

4 Wall Street analysts have issued 1-year price targets for Clearside Biomedical's stock. Their forecasts range from $4.00 to $6.00. On average, they anticipate Clearside Biomedical's stock price to reach $5.00 in the next year. This suggests a possible upside of 222.6% from the stock's current price. View analysts' price targets for Clearside Biomedical.

What are Wall Street analysts saying about Clearside Biomedical stock?

Here are some recent quotes from research analysts about Clearside Biomedical stock:
  • 1. According to Zacks Investment Research, "Clearside Biomedical, Inc. is a biopharmaceutical company is engaged in developing first-in-class drug therapies to treat blinding diseases of the eye using Clearside proprietary suprachoroidal space(TM) microinjector. Its products include CLS-1001 for the treatment of macular edema associated with non-infectious uveitis; CLS-1003 for the treatment of macular edema associated with retinal vein occlusion; and CLS-1002 program for the treatment of wet age-related macular degeneration. Clearside Biomedical, Inc. is headquartered in Alpharetta, Georgia. " (1/29/2020)
  • 2. Wedbush analysts commented, "Our $69 price target is based on probability-adjusted revenue forecasts for luspatercept, the company’s earlier stage pipeline and estimated year-end cash. We use the net present value of our revenue forecast through 2026, apply a 65% probability of success and a 2.5x price/sales multiple for luspatercept, and our year-end cash estimate of $7.49 to arrive at our price target. We use a 20% discount rate for the pipeline as it is above the marketed products discount rate due to development risks but within the typical range of 15-25% for products in development." (8/6/2019)

Has Clearside Biomedical been receiving favorable news coverage?

Media coverage about CLSD stock has trended very negative on Wednesday, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Clearside Biomedical earned a media sentiment score of -3.3 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the next several days. View the latest news aboutClearside Biomedical.

Who are some of Clearside Biomedical's key competitors?

What other stocks do shareholders of Clearside Biomedical own?

Who are Clearside Biomedical's key executives?

Clearside Biomedical's management team includes the following people:
  • Dr. George M. Lasezkay Pharma.D., J.D., Interim CEO & Director (Age 67)
  • Mr. Charles A. Deignan, Chief Financial Officer (Age 55)
  • Mr. Stephen C. Kilmer, Investor Relations Officer (Age 53)
  • Mr. Leslie B. Zacks, Gen. Counsel, Chief Compliance Officer & Sec. (Age 50)
  • Mr. Rick McElheny, VP of Corp. Devel.

When did Clearside Biomedical IPO?

(CLSD) raised $50 million in an initial public offering on Thursday, June 2nd 2016. The company issued 7,200,000 shares at $7.00 per share. Cowen and Company and Stifel acted as the underwriters for the IPO and Needham & Company, Wedbush PacGrow was co-manager.

What is Clearside Biomedical's stock symbol?

Clearside Biomedical trades on the NASDAQ under the ticker symbol "CLSD."

How do I buy shares of Clearside Biomedical?

Shares of CLSD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Clearside Biomedical's stock price today?

One share of CLSD stock can currently be purchased for approximately $1.55.

How big of a company is Clearside Biomedical?

Clearside Biomedical has a market capitalization of $69.55 million and generates $2.17 million in revenue each year. The company earns $-30,770,000.00 in net income (profit) each year or ($0.81) on an earnings per share basis. Clearside Biomedical employs 50 workers across the globe. View additional information about Clearside Biomedical.

What is Clearside Biomedical's official website?

The official website for Clearside Biomedical is http://www.clearsidebio.com/.

How can I contact Clearside Biomedical?

Clearside Biomedical's mailing address is 900 NORTH POINT PARKWAY SUITE 200, ALPHARETTA GA, 30005. The company can be reached via phone at 678-270-3631 or via email at [email protected]


MarketBeat Community Rating for Clearside Biomedical (NASDAQ CLSD)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  296 (Vote Outperform)
Underperform Votes:  248 (Vote Underperform)
Total Votes:  544
MarketBeat's community ratings are surveys of what our community members think about Clearside Biomedical and other stocks. Vote "Outperform" if you believe CLSD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CLSD will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/1/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel